Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
Genmab ph. 2 data spur claim ADC ‘clearly superior’ to Elahere
Genmab reported progression-free survival of 9.5 months, leading TD Cowen analysts to hail the asset as “clearly superior” to AbbVie’s Elahere.
Nick Paul Taylor
Oct 5, 2026 4:14am
AstraZeneca scales Summit’s PD-1xVEGF combos with $2B investment
Sep 29, 2026 3:07am
Merck and Daiichi pull lung cancer filing after FDA pushback
Sep 28, 2026 4:30am
Roche notches ph. 3 lung cancer win but trails GSK on survival
Sep 14, 2026 5:50am
GSK’s ADC lays down marker for lung cancer scrap with Merck
Sep 12, 2026 7:00pm
Pfizer offloads scrapped Seagen ADC to Medicus Pharma
Sep 3, 2026 11:31am
